CD274 and neoplasm: Median OS with nivolumab vs. with everolimus: in PD-L1+ patients, 21.8 vs. 18.8 months; in PD-L1− patients, 27.4 vs. 21.2 months; PD-L1+ cutoff: ≥1% tumor cells, membranous expression, Dako assay; prevalence: 24%